Luma Group said it has completed the final close of LumaBio Fund I at $410 million, giving the New York-based investor a sizable first dedicated pool of life sciences capital with an unusually long 15-year structure.
The firm said the fund has already invested in more than 10 biotechs, including Character Biosciences, Coultreon Biopharma and Altos Labs. The setup matters because it points to an investment model built around holding periods long enough to finance companies through multiple technical and commercial milestones rather than relying on a quicker exit cycle.
The fund structure
According to Luma, the fund is intended to back life sciences companies from discovery to commercialization. That longer duration stands out in a sector where development timelines can extend well beyond a traditional venture cadence, particularly for companies moving from platform work into clinical testing and manufacturing scale-up.
Joshua Fink, founder and managing member of Luma Group, said the firm was founded in 2023 on the belief that patient, long-term capital can help translate strong science into medicines. The strategic signal is less about one financing event than about where some investors still see opportunity: concentrated support for biotech programs that may need time to mature operationally as well as scientifically.
Portfolio signal
Luma pointed to an early validation event from Vaccine Company, a business it co-founded that Eli Lilly agreed to acquire earlier this year for up to $1.55 billion. Fierce Biotech said the target was focused on in vivo nanoparticle technology and that the deal was one of three vaccine acquisitions by Lilly in 2026.
For the market, the message is that fresh capital is still being raised for biotech, but here it is tied to duration and company building, not just asset picking.
